[1]Baranowska-Kortylewicz J. Radioactive drugs in drug development research: quality assurance issues[J]. Mini-Reviews in Medicinal Chemistry, 2007, 7(3): 231-244.
[2]国家药典委员会. 中华人民共和国药典2015年版[M]. 北京:化学工业出版社,2015.
[3]European Directorate for the Quality of Medicines & HealthCare. European Pharmacopoeia 9.0[M]. London :European Directorate for the Quality of Medicines & HealthCare, 2016.
[4]The United States Pharmacopeia Convention. United States Pharmacopeia/National Formulary (USP42-NF37)[M]. Washington: United States Pharmacopeia Origination Press, 2018.
[5]姜典卓. 放射性药品国家标准现状及2015年版《中国药典》中主要增修订内容介绍[J]. 中国药学杂志,2015,50(20):1770-1772.
Jiang Dianzhuo. Introduction to the national drug standards of radiopharmaceutical preparations and the main revision in the chinese pharmacopoeia 2015 edition[J]. Chinese Pharmaceutical Journal, 2015, 50(20): 1770-1772(in Chinese).
[6]Erik B, Rory Z, Wouter B. Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals[J]. The Journal of Nuclear Medicine, 2019, 4(1): 1-13.
[7]Nakao R, Furutuka K, Yamaguchi M, et al. Quality control of PET radiopharmaceuticals using HPLC with electrochemical detection[J]. Nuclear Medicine and Biology, 2005, 33(3): 441-447.
[8]Wynendaele E, Bracke N, Stalmans S, et al. Development of peptide and protein based radio-pharmaceuticals[J]. Current Pharmaceutical Design, 2014, 20(14): 2 250-67.
[9]王正,徐建锋,蔡玉婷,等. 中国放射性药物的现状及发展趋势[J]. 中国食品药品监管,2018,7(2):44-49.
Wang Zheng, Xu Jianfeng, Cai Yuting, et al. Current status and development trend of radiopharmaceuticals in China[J]. China Food & Drug Administration Magazine, 2018, 7(2): 44-499(in Chinese).
[10]光红梅,王庆利. EMA对放射性诊断药品的非临床评价要求介绍[J]. 中国新药杂志,2018,27(18):2111-2115.
Guang Hongmei, Wang Qingli. Introduction to EMA non-clinical evaluation of radiopharmaceuticals for medical diagnosis[J]. Chinese Journal of New Drugs, 2018, 27(18): 2111-2115(in Chinese). |